“We are thrilled to welcome Kateric to our high-performing portfolio of medical writing services,” said Michael Stomberg, CEO of ProPharma Group,”

CHICAGO (PRWEB)
September 01, 2022

Since 2004, Kateric has established a reputation as a strategic partner throughout the life sciences industry providing worldwide access to regulatory documentation services and capabilities over a range of product lifecycle needs. Through this acquisition, ProPharma Group immediately expands and substantially enhances its comprehensive suite of medical writing services. Mary Culliton, Founder, and President of Kateric, will lead ProPharma Group’s Global Medical Writing Business Unit, as Senior Vice President of Global Medical Writing, bringing with her 30 years of pharmaceutical industry experience.

“We are thrilled to welcome Kateric to our high-performing portfolio of medical writing services,” said Michael Stomberg, CEO of ProPharma Group. “This is an incredible opportunity to supplement ProPharma Group’s services and stay ahead of the significant medical writing demand worldwide. With the leadership of Kateric’s highly successful management team, collaborating with our existing infrastructure, we are confident in our ability to seize the enormous opportunities ahead to support our clients as the market leader in this segment.”

“We celebrate this significant partnership today as we formally join the ProPharma Group family,” said Mary Culliton, Kateric Founder, and President. “Under the ProPharma Group brand, we will combine our decades of experience to push the boundaries of medical writing, augment growth and innovation in the industry, and remain focused on consistently delivering outstanding capabilities and services to the life sciences industry.”

For companies across the globe, ProPharma Group and Kateric have delivered medical writing expertise in all major therapeutic areas and stages of development. The company’s quality medical writing solutions can be customized to serve clients of any size – from small, virtual biotech firms to global pharmaceutical companies.

For more information visit Kateric has joined ProPharma Group.

About ProPharma Group

ProPharma Group is the global, independent, single-source provider of regulatory, clinical, and compliance services serving pharmaceutical, biotechnology, and medical device companies. Founded in 2001, ProPharma Group has more than 2500 colleagues worldwide providing solutions to complex challenges in a dynamic regulatory environment. With the mission to improve the health and safety of patients, ProPharma Group is focused on delivering the highest quality services throughout the full product lifecycle including regulatory sciences, clinical research solutions, life science consulting, R&D technology, pharmacovigilance, and medical information services. For more information, please visit http://www.propharmagroup.com.

About Kateric

Since 2004, Kateric has been partnering with biopharmaceutical companies worldwide to strategically provide individualized, single source solutions across an expansive document and therapy area portfolio encompassing biopharmaceuticals, devices, and diagnostics. With a global footprint across the United States, Canada, Europe, and India, Kateric’s team of talented regulatory writers are experts at distilling and assimilating scientific data to autonomously produce clear, concise, high-quality deliverables according to a systematic approach, seamlessly integrating with study teams and providing expert stakeholder and project management. As a collaborative and flexible partner, Kateric consistently endeavors to find ways to optimize processes and share innovations with its clients that can maximize value and efficiency and reduce cost, while maintaining quality.

About Odyssey Investment Partners

Odyssey Investment Partners, with offices in New York and Los Angeles, is a leading private equity investment firm with more than a 25-year history of partnering with skilled managers to transform middle-market companies into more efficient and diversified businesses with strong growth profiles. Odyssey makes majority-controlled investments in industries with a long-term positive outlook and favorable secular trends. For further information about Odyssey, please visit http://www.odysseyinvestment.com.

Share article on social media or email:

Ero Health

“The achievement of our HITRUST certification is but one demonstration of Ero Health’s commitment to investing in our customers for the future,” said Steve Rhodes, Ero Health Co-CEO.

ST. LOUIS (PRWEB)
September 01, 2022

Ero Health, a leading healthcare IT services firm and the largest solution partner focused on implementation, consulting and data services for eClinicalWorks EHR solutions, announced the hosted eClinicalWorks Servers residing at Data Foundry, FOGO and Switch Networks, and the Revenue Cycle Management residing at Dardenne Prairie, have each earned Certified status for information security by HITRUST.

HITRUST Risk-based, 2-year (r2) Certified status demonstrates that the organization’s hosted eClinicalWorks servers and Revenue Cycle Management have met key regulations and industry-defined requirements and is appropriately managing risk. This achievement places Ero Health in an elite group of organizations worldwide that have earned this certification. By including federal and state regulations, standards, and frameworks, and incorporating a risk-based approach, the HITRUST Assurance Program helps organizations address security and data protection challenges through a comprehensive and flexible framework of prescriptive and scalable security controls.

“The achievement of our HITRUST certification is but one demonstration of Ero Health’s commitment to investing in our customers for the future,” said Steve Rhodes, Ero Health Co-CEO. “Since our founding, we’ve always focused on going above and beyond to serve our customers. We believe that the rigorous HITRUST certification process has allowed us to ensure the highest standards for the security and integrity of our hosted eClinicalWorks servers and Revenue Cycle Management. This is an investment that we felt important to best serve our customers.”

According to its website, HITRUST champions programs that safeguard sensitive information and manage information risk for organizations around the world. The HITRUST cybersecurity framework addresses a multitude of security and privacy issues, as well as federal and state regulations, standards, and frameworks, leveraging a risk-based approach to support organizations in their development and maintenance of security and privacy controls.

“The HITRUST Assurance Program is the most rigorous available, consisting of a multitude of quality assurance checks, both automated and manual,” said Bimal Sheth, Executive Vice President, Standards Development & Assurance Operations, HITRUST. “The fact that Ero Health has achieved HITRUST Risk-based, 2-year Certification attests to the high quality of their information risk management and compliance program.”

Ero Health achieved its HITRUST 2-year Certification in May, 2022 after a two-year assessment process.

“The security and integrity of our data is especially important in the hosting and RCM space,” said Num Pisutha-Arnond, Ero Health Co-CEO. “We take that quite seriously, and that’s why going well beyond the widely adopted SOC 2 guidelines was something we felt strongly about. Not only does it set Ero Health’s procedures and protocols apart from others in our space, but it also demonstrates our willingness to put in the hard work for our customers.”

About Ero Health

Formed as the result of a merger between Curas, Inc. and Physicians Trust in 2019, Ero Health is the largest eClinicalWorks Partner in North America that provides a full suite of digital health services to healthcare systems, clinics, and physician practices. This includes payers, IPA’s, ACOs, and community health centers. The firm focuses on helping practices gain greater visibility to patient data, reduce overhead costs and improve patient and staff satisfaction. As an expert in successfully optimizing your eClinicalWorks investment in EMR and Practice Management, Ero Health provides everything from adoption to training, support, hosting, data analytics, and revenue cycle management. Headquartered in St. Louis, MO, Ero Health has additional offices in Santa Ana, CA, Atlanta, GA, Toronto, and Vancouver, Canada, with data centers in Austin, TX, and Atlanta, GA. For more information, visit ero.health.

Share article on social media or email:

Oransi is a leading air purification company known for its efficient, intuitive and reliable products.

“We’re excited to partner with Oransi to improve the air quality in our skilled nursing facilities and rehabilitative care centers in Oklahoma and Texas,” said Michelle Ridgley, Corporate Operations and Project Manager at Senior Living Properties LLC.

RADFORD, Va. (PRWEB)
September 01, 2022

Oransi, a leading air purification company known for its efficient, intuitive and reliable products, today announced it partnered with Senior Living Properties, LLC to deliver 250 Mod air purifiers to its skilled nursing facilities and rehabilitation care centers across Oklahoma and Texas. The Virginia-based air purifier brand’s award-winning Mod air purifier quietly cleans 99.6% of virus-sized particles and airborne particulates from a 1250 square foot room two times per hour. Senior Living Properties is using the new Mod air purifiers from Oransi to create safer visitation spaces for its residents, staff and visitors.

“We’re excited to partner with Oransi to improve the air quality in our skilled nursing facilities and rehabilitative care centers in Oklahoma and Texas,” said Michelle Ridgley, Corporate Operations and Project Manager at Senior Living Properties LLC. “Creating a safer environment for residents allows us to have in-person visitors, something loved ones sorely missed during the worst of the pandemic when visitations were limited. Our continued goal is to create healthier spaces for our residents, staff and visitors and our partnership with Oransi is a key step in that process,” concluded Ridgley.

The Centers for Medicare & Medicaid (CMS) presently is offering up to $3000 Civil Money Penalty funding per facility to nursing homes to protect indoor air quality in visitation areas. Applications are due by September 30, 2022 for most states. The opportunity is second chance funding and nursing home facilities can receive up to $3000 from CMS for air purifiers even if they already received that amount in the first round of funding.

“We’re honored that Senior Living Properties selected Oransi air purifiers to help mitigate the risk of COVID-19 in their common areas,” said Peter Mann, CEO of Oransi. “Our Mod and Mod jr. air purifiers meet all criteria for nursing home funding. This year we sold more than 5,000 air purifiers to nursing homes. Our air purifiers also were selected by the Javits Center for its field hospital early in the pandemic. The importance of healthy indoor air has never been more crucial, especially for vulnerable populations. Real HEPA air purifiers can make indoor spaces safer and help people in nursing homes maintain vital in-person connections with loved ones – and we’re thrilled to be able to make that happen.”

For more information on Oransi air purifier solutions for nursing homes or for assistance with filing for government funding email sales (at) oransi.com.

About SLP OPERATIONS LLC

Headquartered in Bedford, SLP Operations LLC provides health care services, including skilled nursing, long-term care, physical and occupational rehabilitation, speech therapy, Alzheimer’s care, wound care management, and respite care. With approximately 3,100 health care team members, Senior Living Properties operates skilled nursing and rehabilitative care centers in rural Texas cities – San Angelo, Borger, Knox City, Carthage, Centerville, Childress, Coleman, New Braunfels, Pampa, Abilene, Brownwood, Electra, Burkburnett, Graham, Hamilton, Haskell, Lubbock, Jacksonville, Waco, Kaufman, Lake Jackson, LaPorte, Llano, Flatonia, Giddings, Overton, Palestine, Paris, Temple, Snyder, Sweetwater, Gainesville, Orange, Texas City, Mineola, Levelland, Johnson City, Comfort, Burleson, Commerce, Garland, Lancaster, Mansfield, Granbury, Willis, Conroe, Diboll, and Tulsa, Oklahoma.

About Oransi

What began as an engineer’s quest to find a better indoor air quality solution for his young asthmatic son, 13 years later has evolved to become a leading air purification company designing some of the most efficient and intuitive products on the market. Based in Radford, Virginia, the veteran-owned business ranked on the 2022 Inc. 5000 list of the fastest-growing private companies. It is managed by a team of executives and engineers with decades of experience in the air quality industry. They are allergy and asthma sufferers themselves, making air purifiers they also use and need. Oransi provides best-in-class HEPA air purifiers to consumers, businesses and those in the health, dental and medical fields. The company believes everyone deserves to breathe clean, fresh air and while performance is most important, they recognize the need for products that are easy to use and reliable.

Media Contact

Ria Romano, Partner

RPR Public Relations, Inc.

Tel. 786-290-6413

Share article on social media or email:

We are thrilled to earn a spot on the Inc. 5000 list for the fourth time, it is exciting to see the continued growth throughout the past three years, which have been a challenging time for everyone. However, our resilience – and building a great team – has made our vision continue to be possible.

PALM HARBOR, Fla. (PRWEB)
September 01, 2022

This month, Inc. revealed that Elite Insurance Partners is No. 3394 on its annual Inc. 5000 list, the most prestigious ranking of the fastest-growing private companies in America. The list represents a one-of-a-kind look at the most successful companies within the economy’s most dynamic segment—its independent businesses. Facebook, Chobani, Under Armour, Microsoft, Patagonia, and many other well-known names gained their first national exposure as honorees on the Inc. 5000.

“We are thrilled to earn a spot on the Inc. 5000 list for the fourth time,” says Jagger Esch, president/CEO of Elite Insurance Partners. “It is exciting to see the continued growth throughout the past three years, which have been a challenging time for everyone. However, our resilience – and building a great team – has made our vision continue to be possible.”

The companies on the 2022 Inc. 5000 have not only been successful, but have also demonstrated resilience amid supply chain woes, labor shortages, and the ongoing impact of Covid-19. Among the top 500, the average median three-year revenue growth rate soared to 2,144 percent. Together, those companies added more than 68,394 jobs over the past three years.

Complete results of the Inc. 5000, including company profiles and an interactive database that can be sorted by industry, region, and other criteria, can be found at http://www.inc.com/inc5000. The top 500 companies are featured in the September issue of Inc. magazine.

“The accomplishment of building one of the fastest-growing companies in the U.S., in light of recent economic roadblocks, cannot be overstated,” says Scott Omelianuk, editor-in-chief of Inc. “Inc. is thrilled to honor the companies that have established themselves through innovation, hard work, and rising to the challenges of today.”

About Elite Insurance Partners

Founded in 2014, Elite Insurance Partners is a multiple award-winning Medicare brokerage and one of the top five in the United States. Representing over 30 carriers and assisting beneficiaries nationwide, their primary market is Medicare, but they also help with: dental, vision, cancer, heart attack, stroke, life, long-term care, and disability insurance. Assisting clients nationwide, their mission has always been simple: provide thorough education on all insurance options and help find the best plan(s) for the needs and budget of each person.

For more information, visit http://www.EliteInsurancePartners.com or their Medicare learning resource center, http://www.MedicareFAQ.com.

CONTACT:

If you would like more information, please contact Evy Kartawinata at EKartawinata@TeamEIP.com

More about Inc. and the Inc. 5000

Methodology

Companies on the 2022 Inc. 5000 are ranked according to percentage revenue growth from 2018 to 2021. To qualify, companies must have been founded and generating revenue by March 31, 2018. They must be U.S.-based, privately held, for-profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2021. (Since then, some on the list may have gone public or been acquired.) The minimum revenue required for 2018 is $100,000; the minimum for 2021 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons. Growth rates used to determine company rankings were calculated to four decimal places. The top 500 companies on the Inc. 5000 are featured in Inc. magazine’s September issue. The entire Inc. 5000 can be found at http://www.inc.com/inc5000.

About Inc.

The world’s most trusted business-media brand, Inc. offers entrepreneurs the knowledge, tools, connections, and community to build great companies. Its award-winning multiplatform content reaches more than 50 million people each month across a variety of channels including websites, newsletters, social media, podcasts, and print. Its prestigious Inc. 5000 list, produced every year since 1982, analyzes company data to recognize the fastest-growing privately held businesses in the United States. The global recognition that comes with inclusion in the 5000 gives the founders of the best businesses an opportunity to engage with an exclusive community of their peers, and the credibility that helps them drive sales and recruit talent. The associated Inc. 5000 Conference & Gala is part of a highly acclaimed portfolio of bespoke events produced by Inc. For more information, visit http://www.inc.com.

For more information on the Inc. 5000 Conference & Gala, visit http://conference.inc.com/

Share article on social media or email:

The FDA encourages the use of in silico clinical trials in which a drug or device is tested against a cohort of virtual patients, therefore providing an empirical basis for appropriate comparative assessment.

TORONTO (PRWEB)
September 01, 2022

In clinical research and development, comparison to a control is highly recommended by regulatory agencies for the purpose of demonstrating evidence of clinical efficacy of a drug or device. The control could be a placebo, a known standard-of-care or an available market-approved drug or device. With some diseases or certain classes of devices, a viable control (prospective or retrospective) may not be feasible for ethical or pragmatic reasons. In addition, this problem is not uncommon in the biotech and medtech industries.

This creates the need for alternative approaches for carrying out comparative evaluation. Computational Modeling and Simulation (CM&S) has been identified by the US Food and Drug Administration (FDA) as a necessary component for developing in silico trial designs, in which the comparator arm is generated using CM&S techniques. The FDA encourages the use of in silico clinical trials in which a drug or device is tested against a cohort of virtual patients, therefore providing an empirical basis for appropriate comparative assessment.

Understanding clinical outcomes, safety, effectiveness and developmental challenges early can impact the investment sponsors put forth towards a new compound or device. Innovative trial designs are needed to maximize existing outcomes data and to leverage advanced computational techniques for making increasingly better decisions, accelerate product development and decision making, while reducing overall R&D costs.

Join Premier Research and InSilicoTrials Technologies for this joint webinar and explore the potential for including in silico modeling & simulation as an integral part of the product development plan.

Join Nach Davé, RPh, MS, Vice President, Development Strategy, Premier Consulting; Abie Ekangaki, PhD, Vice President, Statistical Consulting, Premier Consulting; and Roberta Bursi, PhD, PMP, Co-Founder and Executive Vice President of Research and Development, InSilicoTrials Technologies, for the live webinar on Thursday, September 22, 2022, at 10am EDT (3pm BST/UK).

For more information, or to register for this event, visit Accelerate Product Approval Using In Silico Modeling & Simulation.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

The addition of Dr. Mizuno and Dr. Mizuno strengthens NDA Partners’ expertise in clinical pharmacology, population PK/PD modeling and simulation, and model-informed clinical study design, and brings exceptional experience within pediatric populations specifically.

WASHINGTON (PRWEB)
September 01, 2022

NDA Partners’ General Manager, Eric Fish, announced today that the firm has strengthened its clinical pharmacology expertise with the addition of Expert Consultants, Dr. Tomoyuki Mizuno and Dr. Kana Mizuno.

Dr. Tomoyuki Mizuno is an Assistant Professor of Pediatrics at the Division of Clinical Pharmacology at Cincinnati Children’s Hospital Medical Center, and the University of Cincinnati, College of Medicine. He is an expert in pediatric clinical pharmacology, pharmacometrics, model-informed precision dosing (MIPD), and pediatric clinical trial design and simulation. His academic research focuses on applying pharmacokinetics-pharmacodynamics (PK/PD) and physiologically based pharmacokinetics (PBPK) modeling and simulation, pharmacometrics, and systems pharmacology approach to develop and implement personalized precision dosing strategies in pediatric and adult patients.

Dr. Kana Mizuno is an Assistant Professor of Pediatrics at the University of Cincinnati, College of Medicine, Division of Clinical Pharmacology at Cincinnati Children’s Hospital Medical Center. She is an expert in pediatric clinical pharmacology, population PK/PD modeling and simulation, and model-informed pediatric clinical study design. Her academic research focuses on precision/personalized medicine and the implementation of modeling and simulation approaches to inform precision dosing and clinical trial design for pediatric populations including neonates and infants.

Dr. Mizuno and Dr. Mizuno serve as leading members of the Cincinnati Pharmacometrics Center of Excellence program providing strategic clinical pharmacology consulting and pharmacometric services to help sponsors determine optimal clinical trial design and pharmacometrics analysis as part of Model-Informed Drug Development (MIDD) and initial Pediatric Study Plans (iPSP).

“The addition of Dr. Mizuno and Dr. Mizuno strengthens NDA Partners’ expertise in clinical pharmacology, population PK/PD modeling and simulation, and model-informed clinical study design, and brings exceptional experience within pediatric populations specifically. They are a welcome addition to our Quantitative Drug Development Strategies Practice, whose experts help companies design, analyze, and interpret optimal product development programs that address their most difficult issues, using efficient study designs and regulatory strategies that have a high likelihood of success and that can accelerate timelines,” said Dr. Michael Eldon, who leads the firm’s Quantitative Drug Development Strategies Practice.

About NDA Partners

NDA Partners, a ProPharma Group company, is a life sciences management consulting and contract development organization focused on providing product development and regulatory services to the pharmaceutical, biotechnology, and medical device industries worldwide. The highly experienced Expert Consultants in NDA Partners include three former FDA Center Directors; the former Chief Executive Officer and Chief Science Officer at the United States Pharmacopeial Convention (USP); an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, product development program design and management, expert consulting, functional teams, project-based solutions, and clinical trial design and management.

Contact

Eric Fish, General Manager

Office: 540-738-2550

FishEric@ndapartners.com

Share article on social media or email:

The new DGSHAPE DWX-53DC dry dental mill boasts innovative features that maximize precision and productivity while also making monitoring and maintenance easier than ever.

“The speed, efficiency and accuracy of this robust, powerful dry mill, combined with its ease of use, cutting-edge monitoring systems, and automated maintenance features, will enable any size dental lab to increase production, precision, and profitability.”– Lisa Aguirre, DGSHAPE Marketing Manager

IRVINE, Calif. (PRWEB)
September 01, 2022

Roland DGA’s DGSHAPE Americas business group, a leading provider of advanced dental milling solutions, 3D printers, and accessories for laboratories and clinicians, has announced the launch of the new DWX-53DC dry dental mill. The DWX-53DC represents the next generation of DWX Series milling solutions, incorporating innovative productivity, efficiency, and convenience features that put this state-of-the-art digital device in a class of its own.

The 5-axis DWX-53DC boasts an enhanced Automatic 6-Disc Changer with 50 percent faster exchange as well as a 15-station Automatic Tool Changer, allowing for incredibly efficient, uninterrupted 24-hour production. In addition, the DWX-53DC features a redesigned, more robust spindle that delivers three times the tool-gripping power than other models for increased speed and predictability when milling PMMA applications. Also new is an innovative 4 mm tool, made exclusively for the DWX-53DC, that allows for 30 percent faster roughing of PMMA than 3 mm tools. Users will appreciate the DWX-53DC’s built-in web camera as well, designed to work in conjunction with the mill’s proprietary VPanel and DGSHAPE Cloud software to provide on-site and remote monitoring. For cleaner milling and easy maintenance, the DWX-53DC features an automated ecosystem with a dedicated extraction unit and connection cable (both included) to remove debris, plus a built-in ionizer that makes PMMA cleanup a breeze.

The DWX-53DC boasts sleek, sturdy construction, including a robust frame and structure that maximize stability when milling for optimum precision and superior esthetic results. Additionally, the DWX-53DC mill’s overall footprint – small compared to other disc-changer models – allows even labs with limited space to expand their production capabilities.

Engineered for smooth, steady performance, the DWX-53DC is driven by a reliable ball-screw system with 5-axis positioning or simultaneous operation. Other noteworthy features, such as automatic machine calibration, automatic air pressure control, and a user-replaceable spindle, further enhance the DWX-53DC’s milling precision, simple operation, and easy maintenance.

DGSHAPE also offers additional options to suit specific DWX-53DC user needs, such as integration with Microsoft Surface Pro, and an optical barcode reader with up to 100 ID patterns available.

“We’re extremely excited about the introduction of the DWX-53DC to our existing family of DGSHAPE milling solutions, which are ushering in a whole new era of digital dentistry,” said DGSHAPE Marketing Manager Lisa Aguirre. “The speed, efficiency and accuracy of this robust, powerful dry mill, combined with its ease of use, cutting-edge monitoring systems, and automated maintenance features, will enable any size dental lab to increase production, precision, and profitability.”

For more information on the new DWX-53DC dental milling machine, visit https://www.rolanddga.com/dwx-53dc. To learn more about the complete DGSHAPE dental product line, visit http://www.dgshapeamericas.com.

About Roland DGA Corporation and DGSHAPE Americas

Roland DGA Corporation serves North and South America as the marketing, sales, distribution and service arm for Roland DG Corporation and its subsidiary, DGSHAPE. Founded in 1981 and listed on the Tokyo Stock Exchange, Roland DG of Hamamatsu, Japan is a worldwide leader in wide-format inkjet printers, engravers, photo impact printers and CNC milling machines. DGSHAPE Americas is the Roland DGA dental business group dedicated to the DGSHAPE line of products, most notable as a market leader in dental milling machines.

Share article on social media or email: